On the stock market since 2014, it operates in the world of health and science. It has 9 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 158% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $362K a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 21 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $5.4M against $362K in annual sales.
The stock sits at $0.0002. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, MJNE sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MJNE is a small company that closed last year at a loss. The road back to profit runs through spending discipline.